LOBEF (Lobe Sciences) 3-1 Month Momentum %: -20.65% (As of Aug. 24, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Lobe Sciences 3-1 Month Momentum %?

Lobe Sciences LOBEF +12.56% 3-1 Month Momentum % is -20.65% as of Aug. 24, 2026. The stock has 2 warning signs investors should review. Among 1,386 Biotechnology companies, Lobe Sciences ranks worse than 81.24% on this metric.

3-1 Month Momentum % is the total return of the stock from 3-month ago to 1-month ago. As of today (2026-08-24), Lobe Sciences's 3-1 Month Momentum % is -20.65%.

The industry rank for Lobe Sciences's 3-1 Month Momentum % or its related term are showing as below:

LOBEF's 3-1 Month Momentum % is ranked worse than
81.24% of 1386 companies
in the Biotechnology industry
Industry Median: -7.29 vs LOBEF: -20.65

Lobe Sciences  (OTCPK:LOBEF) 3-1 Month Momentum % Explanation

Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 3-1 Month Momentum % measures the total return to a stock over the past three months, but ignores the previous month.

The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.

Lobe Sciences 3-1 Month Momentum % Related Terms

LOBEF vs VRTX, REGN, RVMD: 3-1 Month Momentum % Comparison

For the Biotechnology subindustry, Lobe Sciences's 3-1 Month Momentum %, along with its competitors' market caps and 3-1 Month Momentum % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Lobe Sciences 3-1 Month Momentum % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Lobe Sciences's 3-1 Month Momentum % distribution charts can be found below:

* The bar in red indicates where Lobe Sciences's 3-1 Month Momentum % falls into.


Lobe Sciences  (OTCPK:LOBEF) 3-1 Month Momentum % Calculation

3-1 Month Momentum % is calculated as following:

3-1 Month Momentum %=( Price 1-month ago / Price 3-month ago - 1 ) * 100 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about 3-1 Month Momentum % →
What does a 3-1 Month Momentum % of -20.65% mean?
Lobe Sciences (LOBEF) has a 3-1 Month Momentum % of -20.65% as of Aug. 24, 2026. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Lobe Sciences and its competitors. According to the industry distribution chart, Lobe Sciences ranks #1126 out of 1386 companies in the Biotechnology industry, placing it in the top 81.2%.
Is Lobe Sciences' 3-1 Month Momentum % too high?
Lobe Sciences' current 3-1 Month Momentum % is -20.65%. Based on the distribution chart, Lobe Sciences ranks #1126 out of 1386 companies in the Biotechnology industry, which is in the bottom quartile relative to peers.
How does Lobe Sciences' 3-1 Month Momentum % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Lobe Sciences ranks #1126 out of 1386 companies for 3-1 Month Momentum %. This places Lobe Sciences in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-1 Month Momentum % for a Biotechnology company?
A good 3-1 Month Momentum % depends on the Biotechnology industry context. However, 3-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-1 Month Momentum % mean?
A high 3-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Lobe Sciences and its competitors. Lobe Sciences's current 3-1 Month Momentum % is -20.65%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lobe Sciences stock overvalued right now?
Lobe Sciences (LOBEF) has a current 3-1 Month Momentum % of -20.65%. The current 3-1 Month Momentum % is -20.65%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-1 Month Momentum % calculated?
3-1 Month Momentum % is calculated from a company's financial statements. For Lobe Sciences (LOBEF), the current 3-1 Month Momentum % is -20.65% as of Aug. 24, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Lobe Sciences Business Description

Other Exchanges LOBE:GermanyLOBE:Canada
Address 1771 Robson Street, No. 1614, Vancouver, BC, CAN, V6G 3B7
Lobe Sciences Ltd is a biopharmaceutical company focused on using lipid technology that develop therapies for orphan and rare diseases. It commercializes Altemia MF, a medical food intended to address nutritional deficiencies associated with sickle cell disease. Through its subsidiaries, the company also holds a majority interest in the development of Conjugated Psilocin for potential use in neurological and psychiatric indications. The company operates in one reportable segment, being the biopharmaceutical development of new medicines.